Tango Therapeutics reported a third quarter 2026 net loss of US$68.39 million and a nine month loss of US$169.25 million, while moving its precision oncology pipeline forward. The new Phase 1/2 combination trial of vopimetostat with ERAS-0015 in MTAP-deleted pancreatic and lung cancers deepens Tango Therapeutics' focus on MTAP-driven tumor biology despite higher recent losses. We will now look at how Tango Therapeutics' investment narrative is affected by deeper vopimetostat combinations...
Promising Phase 1/2 data from combination study of vopimetostat plus daraxonrasib presented at 2026 ESMO Congress demonstrated 82% objective response rate (ORR) and 88% 9-month progression-free survival (PFS) rate in patients with 2L/3L pancreatic cancer; combination was generally well-tolerated at go-forward dose Registrational Phase 3 study of vopimetostat plus daraxonrasib as front-line treatment for patients with MTAP-deleted pancreatic cancer expected to be initiated in 1H 2027 Data from vo
Tango Therapeutics combination therapy showed an 82% ORR and 88% 9-month PFS, with median PFS not yet reached, supporting advancement to Phase 3. Learn more about TNGX stock here.
Detailed price information for Tango Therapeutics Inc (TNGX-Q) from The Globe and Mail including charting and trades.
Tango Therapeutics beat expectations Friday for its combination using Revolution Medicines' newly approved drug in pancreatic cancer.
Detailed price information for Pfizer Inc (PFE-N) from The Globe and Mail including charting and trades.
Detailed price information for United Therapeutic (UTHR-Q) from The Globe and Mail including charting and trades.
Detailed price information for Tango Therapeutics Inc (TNGX-Q) from The Globe and Mail including charting and trades.
Tango Therapeutics (TNGX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Tango Therapeutics stock reaction and recent performance Tango Therapeutics (TNGX) has drawn investor attention after recent trading moves, with the stock closing at US$22.76 on the latest trading day. The price change offers a fresh prompt to reassess the company’s recent performance. Over the past month, Tango Therapeutics stock has fallen about 22%, while the past 3 months show a gain of roughly 13%. Year to date, the stock return is about 155%, and the 1-year total return is about...
BOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) (Tango Therapeutics or the Company) today announced that, effective September 1, 2026, the Compensation Committee of Tango Therapeutics' Board of Directors granted a non-qualified stock option to purchase 146,500 shares of its common stock and 40,000 restricted stock units (RSUs) to a new employee under Tango Therapeutics' 2023 Inducement Plan. The Tango Therapeutics 2023 Inducement Plan is used exclusively for th
BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) (“Tango Therapeutics” or the “Company”) today announced that members of the management team are scheduled to participate in a fireside chat at the 2026 Cantor Global Healthcare Conference on Wednesday, September 9, 2026 at 8:35 AM EDT. The live webcast will be available under the "Events & Presentations" tab on the “Investors” page of the Company's website on the day of the event. A replay of the webcast will be a
This is the newest page. Registered accounts read further back.